 A clinical trial sponsored by the National Cancer Institute tested the ability of Rapamycin to decrease the activity of proteins that are regulated by mTOR in both benign and cancerous tumour tissue in Cowden syndrome patients NCT00971789. Only patients over the age of 18 years were included and multiple biopsies were performed before starting treatment and during therapy with Rapamycin. 